Quest Diagnostics stock holds steady after latest results
Veröffentlicht: 19.07.2026 um 05:41 Uhr, Redaktion AD HOC NEWS, Redaktionelle Verantwortung: Rafael Müller (Chefredaktion)
Quest Diagnostics (ISIN US74834L1008) remains a closely watched name for health care investors because its latest reported quarter and market valuation provide the clearest evidence for the stock story. The company reported revenue of $2.58 billion in the first quarter of 2026, adjusted diluted EPS of $2.21, and adjusted operating income of $397 million in that period.
Q1 2026 shows the margin mix
The first-quarter 2026 revenue of $2.58 billion gives the core scale of the business, while adjusted operating income of $397 million shows how profit conversion is holding up. Adjusted diluted EPS of $2.21 in Q1 2026 adds a second profitability marker that investors can compare with prior periods.
Profitability stays central
The comparison that matters most is the year-over-year frame built into the quarter: Quest Diagnostics is operating with $2.58 billion of revenue in Q1 2026 and $397 million of adjusted operating income, a combination that points to a business still focused on margin discipline. A first-quarter EPS line of $2.21 gives a concrete earnings reference point for the year.
Quest Diagnostics latest investor material
The companys own investor relations page remains the natural place to track filings, releases, and upcoming disclosure dates.
Representative product line
Quest Diagnostics is best known for laboratory testing services, which sit at the center of its reporting cadence and quarterly revenue base. That makes the testing platform and service mix more important than any single headline product in understanding the stock.
Market value and trading context
The stock paragraph is limited to what can be stated safely without a live quote: Quest Diagnostics is a large-cap laboratory services company with a public market valuation that moves with earnings quality, reimbursement trends, and operating leverage. For a current trading view, the valuation discussion should be read alongside the latest quarter rather than as a pure price story.
Quest Diagnostics at a glance
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- Ticker: NYSE: DGX
- Trading venue: NYSE
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: S&P 500
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
